How we used a hybrid qual-quant methodology to assess the market opportunity for a new rare disease treatment
Our client is a recently established independent biopharmaceutical company specialising in small molecule development. They were developing a new oral compound for the treatment of a rare genetic disease for which the standard treatment is administered intravenously, however a large proportion of patients receive monitoring only or remain undiagnosed. Their objective was to successfully launch their product in order to provide clinically meaningful benefits to patients and contribute to the overall growth of their business.
How we used behavioural economic theory to reveal fresh insights into patient compliance
Our client currently has a product for a chronic rare disease which has seen an initial successful uptake. HCPs appear to support the product and are actively prescribing it to suitable patients.
However, sales data suggests that repeat prescriptions drastically reduce after the first 3-6 months. Although the product has a known SE profile, our client believes that this can be well managed and controlled.
How we assessed the opportunity for a rare disease product in emerging markets
Our client had a product indicated for a rare Haematology disease. Whilst this product was successfully launched in over 40 countries globally, it had a limited presence in many emerging markets. Our client needed to conduct market research in order to determine how to maximise the commercial opportunities in each of these different emerging markets.
EphMRA 2017 round up
We were delighted to present, exhibit and sponsor this year’s EphMRA Annual Conference in Amsterdam, Netherlands.
We were delighted to present, exhibit and sponsor this year’s EphMRA Annual Conference in Amsterdam, Netherlands. Director and EphMRA board member, Richard Head, Director, Jennifer Redfearn and Associate Director, An-hwa Lee represented us at the conference.
Rare diseases: The market opportunity and market research considerations
Request your complimentary copy of our guide to rare diseases
Last year the FDA approved 48 drugs in rare diseases, including both novel and re-purposed drugs. The opportunity for rare diseases has become significant as manufacturers of orphan drugs are being awarded longer market exclusivity, reduced regulatory fees and tax incentives. However, commercialization of orphan drugs can be challenging, because of the size of patient populations, the cost of drugs, and the difficulty in diagnosing conditions. A successful product launch relies on insightful market intelligence to leverage the opportunity.
However, conducting effective research for rare diseases can be challenging. Drawing upon our considerable experience of managing both small and large scale studies across a number of different diseases, we have created a guide outlining the key steps required to implement an effective market research programme.